Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| plasmacytoid dendritic cell | 13 studies | 34% ± 11% | |
| CD16-positive, CD56-dim natural killer cell, human | 5 studies | 18% ± 2% | |
| CD8-positive, alpha-beta T cell | 4 studies | 17% ± 1% | |
| natural killer cell | 3 studies | 16% ± 1% |
Insufficient scRNA-seq data for expression of PARP10 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| thymus | 100% | 5752.73 | 653 / 653 | 99% | 51.49 | 601 / 605 |
| pancreas | 99% | 2583.79 | 325 / 328 | 100% | 47.18 | 178 / 178 |
| kidney | 100% | 7399.61 | 89 / 89 | 99% | 47.89 | 891 / 901 |
| liver | 100% | 4603.68 | 226 / 226 | 99% | 55.31 | 400 / 406 |
| ovary | 100% | 6611.21 | 180 / 180 | 98% | 67.10 | 423 / 430 |
| esophagus | 100% | 3702.11 | 1444 / 1445 | 98% | 32.24 | 180 / 183 |
| intestine | 100% | 5719.43 | 966 / 966 | 98% | 40.00 | 516 / 527 |
| uterus | 100% | 5994.14 | 170 / 170 | 98% | 49.57 | 449 / 459 |
| prostate | 100% | 7571.53 | 245 / 245 | 97% | 61.35 | 489 / 502 |
| skin | 100% | 3285.38 | 1806 / 1809 | 97% | 58.14 | 460 / 472 |
| lung | 100% | 6209.32 | 578 / 578 | 97% | 41.70 | 1119 / 1155 |
| breast | 100% | 4699.76 | 459 / 459 | 96% | 55.31 | 1075 / 1118 |
| stomach | 100% | 3666.92 | 359 / 359 | 96% | 37.01 | 275 / 286 |
| bladder | 100% | 3174.05 | 21 / 21 | 96% | 45.45 | 483 / 504 |
| adrenal gland | 100% | 6707.14 | 258 / 258 | 95% | 38.02 | 219 / 230 |
| brain | 92% | 1414.03 | 2427 / 2642 | 92% | 25.66 | 651 / 705 |
| adipose | 100% | 4440.43 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 100% | 77.66 | 80 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 94.01 | 29 / 29 |
| spleen | 100% | 11836.57 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 55.05 | 45 / 45 |
| peripheral blood | 99% | 6277.24 | 921 / 929 | 0% | 0 | 0 / 0 |
| blood vessel | 99% | 2736.57 | 1318 / 1335 | 0% | 0 | 0 / 0 |
| heart | 87% | 1424.36 | 745 / 861 | 0% | 0 | 0 / 0 |
| muscle | 85% | 1327.29 | 680 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006325 | Biological process | chromatin organization |
| GO_0048147 | Biological process | negative regulation of fibroblast proliferation |
| GO_0034356 | Biological process | NAD biosynthesis via nicotinamide riboside salvage pathway |
| GO_1900045 | Biological process | negative regulation of protein K63-linked ubiquitination |
| GO_0010629 | Biological process | negative regulation of gene expression |
| GO_0032088 | Biological process | negative regulation of NF-kappaB transcription factor activity |
| GO_0070212 | Biological process | protein poly-ADP-ribosylation |
| GO_0019082 | Biological process | viral protein processing |
| GO_0019985 | Biological process | translesion synthesis |
| GO_0070213 | Biological process | protein auto-ADP-ribosylation |
| GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
| GO_0005730 | Cellular component | nucleolus |
| GO_0005794 | Cellular component | Golgi apparatus |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0016779 | Molecular function | nucleotidyltransferase activity |
| GO_0140297 | Molecular function | DNA-binding transcription factor binding |
| GO_0003950 | Molecular function | NAD+ ADP-ribosyltransferase activity |
| GO_0070530 | Molecular function | K63-linked polyubiquitin modification-dependent protein binding |
| GO_0003714 | Molecular function | transcription corepressor activity |
| GO_0140804 | Molecular function | NAD+- protein-lysine ADP-ribosyltransferase activity |
| GO_1990404 | Molecular function | NAD+-protein ADP-ribosyltransferase activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | PARP10 |
| Protein name | Protein mono-ADP-ribosyltransferase PARP10 (EC 2.4.2.-) (ADP-ribosyltransferase diphtheria toxin-like 10) (ARTD10) (Poly [ADP-ribose] polymerase 10) (PARP-10) Poly(ADP-ribose) polymerase family member 10 Poly [ADP-ribose] polymerase (PARP) (EC 2.4.2.-) |
| Synonyms | |
| Description | FUNCTION: ADP-ribosyltransferase that mediates mono-ADP-ribosylation of glutamate and aspartate residues on target proteins . In contrast to PARP1 and PARP2, it is not able to mediate poly-ADP-ribosylation . Catalyzes mono-ADP-ribosylation of GSK3B, leading to negatively regulate GSK3B kinase activity . Involved in translesion DNA synthesis in response to DNA damage via its interaction with PCNA . . |
| Accessions | E9PSG8 E9PQQ6 E9PPU2 Q53GL7 E9PIA6 ENST00000525486.5 ENST00000313028.12 ENST00000524918.5 ENST00000531537.5 ENST00000527262.5 E9PLE8 ENST00000532311.5 ENST00000530478.5 E9PM86 E9PPE7 E9PPV8 ENST00000528914.5 ENST00000525773.5 ENST00000313059.9 ENST00000528625.5 ENST00000529842.5 F8W8G7 E9PJI2 E9PIK9 E9PSE7 ENST00000528136.5 A2RUM0 ENST00000531707.1 ENST00000529311.5 E9PK67 ENST00000525879.5 E9PNI7 |
